Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical PatientsAlexander T Cohen, Victor F. Tapson, Theodore E. Spiro et al.|New England Journal of Medicine|2013Cited by 603
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesAnnemarie Thompson, Kim A. Williams, Nathaniel R. Smilowitz et al.|Circulation|2024Cited by 284
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac SurgeryAnnemarie Thompson, Kim A. Williams, Kirsten E. Fleischmann et al.|Journal of the American College of Cardiology|2024Cited by 156
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Victor F. Tapson, Theodore E. Spiro et al.|Journal of Thrombosis and Thrombolysis|2011Cited by 120
D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trialAlexander T. Cohen, Paul Burton, Theodore E. Spiro et al.|Journal of Thrombosis and Haemostasis|2014Cited by 115